[FATE] Fate Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.83 Change: 0.05 (1.8%)
Ext. hours: Change: 0 (0%)

chart FATE

Refresh chart

Strongest Trends Summary For FATE

FATE is in the medium-term up 23% above S&P in 8 months. In the long-term up 244% above S&P in 2 years and up 810% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its hematopoietic stem cell (HSC) modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person?s lifespan; and satellite cell modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person?s lifespan. The company?s lead product candidate includes ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies. It is developing pharmacologically optimized HSC therapeutics for the treatment of lysosomal storage disorders within the central nervous system; and Wnt7a Analogs that is in preclinical studies for regeneration in muscular dy

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-60.2% ROE-126.04% ROI
Current Ratio6.67 Quick Ratio Long Term Debt/Equity Debt Ratio0.3
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities70 K Cash From Investing Activities-450 K Cash From Operating Activities-6.38 M Gross Profit
Net Profit-7.88 M Operating Profit-7.32 M Total Assets44.49 M Total Current Assets42.79 M
Total Current Liabilities6.41 M Total Debt19.67 M Total Liabilities23.24 M Total Revenue
Technical Data
High 52 week17.59 Low 52 week7.8 Last close13.85 Last change-1.42%
RSI30.71 Average true range1 Beta1.29 Volume25.46 K
Simple moving average 20 days-10.74% Simple moving average 50 days-6.2% Simple moving average 200 days8.69%
Performance Data
Performance Week-3.55% Performance Month-6.29% Performance Quart1.76% Performance Half41.62%
Performance Year58.29% Performance Year-to-date7.95% Volatility daily4.18% Volatility weekly9.35%
Volatility monthly19.16% Volatility yearly66.37% Relative Volume139.39% Average Volume832.44 K
New High New Low

News

2019-03-18 08:00:00 | Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors

2019-03-06 01:19:38 | Fate Therapeutics Inc FATE Q4 2018 Earnings Conference Call Transcript

2019-03-06 00:33:18 | Edited Transcript of FATE earnings conference call or presentation 5-Mar-19 10:00pm GMT

2019-03-05 16:01:00 | Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress

2019-03-05 15:00:00 | Fate Therapeutics, Inc. to Host Earnings Call

2019-02-28 16:43:34 | Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results

2019-02-28 10:43:03 | Cronos CRON to Report Q4 Earnings: What's in the Cards?

2019-02-25 10:30:03 | Fate Therapeutics FATE Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2019-02-25 07:30:00 | Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International — Emerging Consolidated Expectations, Analyst Ratings

2019-02-22 08:00:00 | Fate Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference

2019-02-20 08:00:00 | Fate Therapeutics Appoints Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation

2019-02-07 16:01:00 | Fate Therapeutics to Present at Guggenheim Healthcare Talks Idea Forum Oncology Day

2019-02-06 08:37:00 | Fate Therapeutics stock up 11% after FDA clears IND application

2019-02-06 08:00:00 | Fate Therapeutics Announces FDA Clearance of IND Application for World’s First Cell Therapy Derived from an Engineered Pluripotent Stem Cell

2019-01-22 11:52:10 | Why Fate Therapeutics, Inc.’s NASDAQ:FATE CEO Pay Matters To You

2018-12-28 09:35:48 | Vanda Pharmaceuticals: Recent Developments and Analyst Ratings

2018-12-19 00:04:46 | Fate Therapeutics Inc FATE Hedge Funds Are Snapping Up

2018-12-04 09:11:02 | Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting

2018-12-03 16:01:00 | Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products

2018-12-03 08:44:01 | Fate Therapeutics FATE Jumps: Stock Rises 8.9%

2018-12-03 07:40:00 | Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences — Discovering Underlying Factors of Influence

2018-11-30 09:30:00 | How Healthcare Is Evolving & Sector Stocks To Watch

2018-11-30 09:10:00 | Shares of Fate Therapeutics up 4.1% in premarket trade after FDA accepts IND application for potential cancer treatment

2018-11-30 08:00:00 | Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy

2018-11-28 12:47:22 | 3 Themes To Watch As Biopharmas 'Bring Some Excitement' In Blood Cancer

2018-11-16 10:35:24 | What Kind Of Shareholder Appears On The Fate Therapeutics Inc’s NASDAQ:FATE Shareholder Register?

2018-11-11 17:42:14 | Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500

2018-11-08 16:01:00 | Fate Therapeutics to Present at Upcoming Investor Conferences

2018-11-02 14:21:21 | Edited Transcript of FATE earnings conference call or presentation 1-Nov-18 9:00pm GMT

2018-11-01 18:40:10 | Fate Therapeutics FATE Reports Q3 Loss, Lags Revenue Estimates

2018-11-01 17:35:40 | Fate Therapeutics: 3Q Earnings Snapshot

2018-11-01 16:01:00 | Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress

2018-11-01 09:01:00 | Fate Therapeutics Announces Seven Presentations at the 2018 ASH Annual Meeting

2018-10-29 16:01:00 | Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2018 Financial Results

2018-10-25 15:55:00 | 3 Healthcare Stocks To Watch On Thursday

2018-10-24 09:10:00 | New Research: Key Drivers of Growth for Workhorse Group, Fate Therapeutics, Minerals Technologies, Tyson Foods, ZAGG, and USA Technologies — Factors of Influence, Major Initiatives and Sustained Production

2018-10-04 08:00:00 | Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations

2018-10-03 07:00:00 | This Biotech Stock Has Quadrupled — and Its Top Shareholder Is Still Buying

2018-09-25 16:01:00 | Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2018-09-25 08:00:00 | Fate Therapeutics to Present at Upcoming Investor Conferences

2018-09-20 23:37:41 | Fate Therapeutics Announces Pricing of Public Offering of Common Stock

2018-09-20 16:11:02 | Fate Therapeutics Announces Proposed Public Offering of Common Stock

2018-09-20 13:32:27 | Why You Need To Look At This Factor Before Buying Fate Therapeutics Inc NASDAQ:FATE

2018-09-17 19:00:00 | Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies

2018-09-13 08:00:00 | Fate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular Reprogramming

2018-08-31 08:10:00 | Research Report Identifies Kronos Worldwide, The Gap, Citigroup, Cadence Design, SPX FLOW, and Fate Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-08-29 16:01:00 | Fate Therapeutics to Present at Upcoming Investor Conferences

2018-08-16 23:35:27 | Edited Transcript of FATE earnings conference call or presentation 6-Aug-18 9:00pm GMT

2018-08-07 16:01:00 | Fate Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

2018-08-06 18:00:10 | Fate Therapeutics FATE Reports Q2 Loss, Lags Revenue Estimates